GGrantIndex
← Leaderboards

Laurence H Kedes

University Of Southern California

$5,584,649
Attributed
$5,584,649
Total exposure
5
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.3M · FY200511
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11

Funding mix

By agency

NIH$17,489,817 · 8

By mechanism

P01$10,973,699 · 4
R01$4,614,960 · 2
P50$1,901,158 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Tissue /Cell Culture

Research focus

Tissue /Cell CultureTranscription FactorTransfectionProtein Protein InteractionMolecular GeneticsGene ExpressionDrug Adverse EffectGene Induction /RepressionGenetic Enhancer ElementDoxorubicinNeoplasm /Cancer TherapyTransfection /Expression VectorLaboratory RatGenetic Promoter ElementGene TherapyEnzyme ActivityMyocardium DisorderGenetically Modified AnimalsProtein DegradationEnzyme InhibitorsCardiotoxinNeoplasm /CancerRetroviridaeLaboratory Mouse

Grant awards (27)

The Skeletal Dysplasias$1,890,010
P01 · FY2011 · HD · contact PI
Doxorubicin Cardiomyopathy: Molecular Genetics & Rescue$450,225
R01 · FY2008 · HL · contact PI
Doxorubicin Cardiomyopathy: Molecular Genetics & Rescue$447,580
R01 · FY2007 · HL · contact PI
Doxorubicin Cardiomyopathy: Molecular Genetics & Rescue$461,096
R01 · FY2006 · HL · contact PI
Improving Retroviral Vectors for Gene Delivery$1,738,820
P01 · FY2005 · CA
Doxorubicin Cardiomyopathy: Molecular Genetics &Rescue$446,834
R01 · FY2005 · HL
Doxorubicin Cardiomyopathy: Molecular Genetics &Rescue$69,334
R01 · FY2005 · HL
Improving Retroviral Vectors for Gene Delivery$1,683,635
P01 · FY2004 · CA
Doxorubicin Cardiomyopathy: Molecular Genetics &Rescue$446,510
R01 · FY2004 · HL
Improving Retroviral Vectors for Gene Delivery$1,584,584
P01 · FY2003 · CA
DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE$464,568
R01 · FY2003 · HL
5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK$456,302
R01 · FY2003 · CA
CO-ACTIVATORS AND REPRESSORS OF MUSCLE TRANSCRIPTION$130,674
P01 · FY2003 · DE
Improving Retroviral Vectors for Gene Delivery$23,623
P01 · FY2003 · CA
Improving Retroviral Vectors for Gene Delivery$1,420,568
P01 · FY2002 · CA
DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE$462,487
R01 · FY2002 · HL
CO-ACTIVATORS AND REPRESSORS OF MUSCLE TRANSCRIPTION$130,674
P01 · FY2002 · DE
Improving Retroviral Vectors for Gene Delivery$1,556,946
P01 · FY2001 · CA
DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE$460,890
R01 · FY2001 · HL
CO-ACTIVATORS AND REPRESSORS OF MUSCLE TRANSCRIPTION$130,674
P01 · FY2001 · DE
SCOR MOLECULAR GENETICS OF HYPERTENSION$1,638,286
P50 · FY2000 · HL
DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE$394,780
R01 · FY2000 · HL
CELLULAR TRANSDUCTION FOR DRUG DELIVERY IN CANCER$368,696
P01 · FY2000 · CA
REGULATION OF GENE EXPRESSION IN HYPERTENSIVE HEARTS$262,872
P50 · FY2000 · HL
MYOBLAST TRANSFER FOR DELIVERY OF ANTINEOPLASTIC AGENTS$184,121
P01 · FY2000 · CA
CO-ACTIVATORS AND REPRESSORS OF MUSCLE TRANSCRIPTION$130,674
P01 · FY2000 · DE
DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE$54,354
R01 · FY2000 · HL